Financial Gravity Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-25
| Closed | -$121 | – | 1551 |
|
|
2024
Q1 | $121 | Buy |
25
+21
| +525% | +$102 | ﹤0.01% | 1702 |
|
|
2023
Q4 | $20 | Buy |
4
+2
| +100% | +$10 | ﹤0.01% | 1431 |
|
|
2023
Q3 | $10 | Sell |
2
-5
| -71% | -$25 | ﹤0.01% | 1161 |
|
|
2023
Q2 | $37 | Sell |
7
-1
| -13% | -$5 | ﹤0.01% | 1434 |
|
|
2023
Q1 | $14 | Sell |
8
-3
| -27% | -$5 | ﹤0.01% | 824 |
|
|
2022
Q4 | $62 | Sell |
11
-15
| -58% | -$85 | ﹤0.01% | 1194 |
|
|
2022
Q3 | $21 | Buy |
26
+4
| +18% | +$3 | ﹤0.01% | 716 |
|
|
2022
Q2 | $18 | Sell |
22
-10
| -31% | -$8 | ﹤0.01% | 647 |
|
|
2022
Q1 | $28 | Buy |
32
+4
| +14% | +$4 | ﹤0.01% | 686 |
|
|
2021
Q4 | $24 | Buy |
28
+26
| +1,300% | +$22 | ﹤0.01% | 811 |
|
|
2021
Q3 | $14K | Hold |
2
| – | – | 0.01% | 844 |
|
|
2021
Q2 | $16K | Sell |
2
-3
| -60% | -$24K | 0.01% | 846 |
|
|
2021
Q1 | $55 | Buy |
+5
| New | +$55 | ﹤0.01% | 546 |
|